IGF-1 LR3 side effects
IGF-1 LR3 side effects in plain English — hypoglycemia, hand numbness, carpal tunnel, headaches, joint aches, and the cancer-axis caveat.
Updated May 7, 2026 · 5 min read
IGF-1 LR3 has the most pronounced side-effect profile of the strength peptides. The acute effects are hypoglycemia, hand numbness, and headaches; the sub-acute effects are carpal tunnel symptoms, joint aches, and fatigue; the long-term concern is the cancer-axis question covered separately. None of these are deal-breakers at conservative doses, but they're more frequent and more intense than what users see from GH secretagogues, and they need to be planned for.
The full side-effect map
| Effect | Frequency | Severity | Onset |
|---|---|---|---|
| Hypoglycemia | Common, dose-dependent | Mild to moderate | Acute, post-injection |
| Hand or foot numbness/tingling | Common | Mild | Within first week |
| Carpal tunnel symptoms | Occasional | Moderate | After 2+ weeks |
| Headaches | Occasional | Mild | Acute or sub-acute |
| Fatigue | Common in week 1 | Mild | First 7–10 days |
| Joint aches | Occasional | Mild | Sub-acute |
| Increased appetite | Common | Variable | Within first few days |
| Injection-site reactions | Uncommon | Mild | Acute |
| Mild facial flushing | Occasional | Mild | Acute |
Hypoglycemia — the most distinctive effect
Hypoglycemia is the IGF-1 LR3 side effect that catches new users off guard. The mechanism is direct: the IGF-1 receptor crossreacts with the insulin receptor, so circulating IGF-1 LR3 produces insulin-like glucose uptake into muscle and adipose tissue.
Symptoms typically appear 30 minutes to 2 hours after injection:
- Lightheadedness, shakiness
- Cold sweat
- Sudden hunger
- Difficulty concentrating
- Tremor in the hands
- In severe cases, confusion or vision changes
The risk is highest when:
- Injecting on an empty stomach
- Pre-workout with no carbohydrate intake before training
- Stacking with insulin (advanced protocol — not for beginners)
- Running aggressive doses (above 50 mcg per injection)
The fix: eat a carbohydrate-containing meal 30–60 minutes before injection. Most users plan injections around meals, not training. If hypoglycemia hits during training, fast carbs (juice, fruit) resolve it within minutes. See IGF-1 LR3 and insulin.
Hand and foot numbness
Tingling or numbness in the hands or feet is common in the first week or two of a cycle. It's caused by mild fluid retention compressing peripheral nerves — a generic feature of supraphysiologic IGF-1 receptor activation.
Most cases:
- Resolve on their own within a week
- Respond to dose reduction
- Are unilateral or come and go
If it persists past 2–3 weeks, becomes bilateral and constant, or progresses to grip weakness, it's becoming carpal tunnel territory.
Carpal tunnel symptoms
Carpal tunnel — numbness in thumb, index, and middle fingers, often with weakness or grip impairment — is a documented complication of GH/IGF-1-axis activation. IGF-1 LR3 produces it more readily than GH secretagogues do because IGF-1 elevation is more direct.
Risk factors:
- Doses above 60 mcg/day
- Cycle length beyond 6 weeks
- Pre-existing repetitive-stress wrist issues (typing, lifting, climbing)
- Stacking with synthetic HGH or high-dose secretagogues
| Severity | Action |
|---|---|
| Mild, intermittent tingling | Reduce dose 25–50%; usually resolves |
| Persistent tingling past 2 weeks | Reduce dose further or stop; symptoms typically resolve in 2–4 weeks |
| Grip weakness or fine-motor loss | Stop immediately; consult a clinician |
Headaches
IGF-1 LR3 can cause mild to moderate headaches, especially in the first week and at higher doses. Mechanism is partly fluid-retention-related and partly a direct neurovascular effect.
Most resolve as the body adapts. Severe persistent headaches, particularly with vision changes, are a stop signal — they can indicate raised intracranial pressure, which is a documented (rare) GH-axis side effect.
Fatigue in week one
A surprising number of users report mild lethargy in the first 7–10 days of a cycle. The mechanism isn't fully clear — possibly related to the metabolic shift toward glucose disposal. It typically resolves as the body adapts. Persistent fatigue past week 2 is unusual and worth dose reduction.
Joint aches
Joint aches — knees, shoulders, lower back — are an occasional complaint, particularly at higher doses or longer cycles. The pattern is similar to what HGH users report, just less intense.
Usually transient. Dose reduction resolves it. Persistent joint pain past cycle end is rare and warrants attention.
Increased appetite
Common. The IGF-1-receptor / insulin-receptor crossreactivity drives glucose uptake, which drops blood glucose, which drives hunger. Most users plan around it. Some find it helpful for bulking; some find it disruptive on cuts.
When to stop
| Symptom | Action |
|---|---|
| Severe persistent hypoglycemia | Stop and re-evaluate dose / timing / nutrition |
| Grip weakness or progressive fine-motor loss | Stop immediately |
| Severe headache with vision changes | Stop immediately, consult clinician |
| New lump, mole change, unusual bleeding | Stop, consult clinician |
| Fasting glucose drops below 70 mg/dL repeatedly | Stop, evaluate insulin sensitivity |
| Joint pain that doesn't resolve with dose reduction | Stop |
The cancer-axis caveat
This is non-negotiable in any IGF-1 LR3 discussion. IGF-1 receptor activation is implicated in cellular proliferation pathways. The acute side effects above are tolerability questions; the long-term concern is the cancer-axis question. Active or recent cancer is an absolute contraindication. Strong family history of hormone-sensitive cancer warrants a clinician conversation before considering a cycle. See cancer concerns.
Drug interactions
- Insulin / oral hypoglycemics — IGF-1 LR3 substantially shifts insulin needs and amplifies hypoglycemia risk. Coordinate with prescribing clinician.
- Synthetic HGH — stacking compounds GH/IGF-1-axis side effects. Generally avoided.
- Corticosteroids — can blunt the anabolic response and shift glucose handling.
Pregnancy and lactation
Not studied. Don't.